Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rigontec Buy Adds RNA Tech To Merck & Co IO Portfolio

Executive Summary

Merck & Co. adds to its immuno-oncology pipeline with the acquisition of Rigontec for an upfront payment of €115m, with the three-year-old company offering Merck a unique approach to immunotherapy and a lead candidate currently in Phase I/II trials, the first of its kind in human studies.

You may also be interested in...



Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V

While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.

Wellington Partners Unveils €210m Eurocentric Biotech/Medtech Fund WPLS-V

With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.

Boehringer Ingelheim Is Getting Bets In Early In IO Space

The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer Ingelheim "a little bit of a head start" on rival pharma companies in identifying technologies that could translate into therapies five years down the line .

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel